Sarepta now needs flawless progress for gene therapy

Overnight, Sarepta became more dependent on its Duchenne muscular dystrophy gene therapy project.

The Food and Drug Administration on Monday rejected Vyondys 53 — and potentially set back another experimental drug called casimersen —​ on safety worries, an action that calls into question lofty revenue forecasts.